Lysosomal dysfunction represents a critical pathological mechanism in progressive supranuclear palsy (PSP), contributing to the accumulation of aberrant proteins, cellular debris, and dysfunctional organelles. The autophagy-lysosome pathway, responsible for cellular homeostasis and clearance of misfolded proteins, is significantly impaired in PSP, leading to the characteristic accumulation of 4R tau filaments and other cellular waste products. This mechanism connects closely with other PSP pathological processes including mitochondrial dysfunction, endoplasmic reticulum stress, and neuroinflammation.
Post-mortem studies reveal significant lysosomal alterations in PSP brain tissue:
Lysosomal pathology in PSP follows a characteristic anatomical pattern[2]:
| Brain Region | Lysosomal Alteration Severity |
|---|---|
| Globus pallidus internus | Severe |
| Substantia nigra | Severe |
| Basal ganglia | Moderate-severe |
| Brainstem nuclei | Moderate |
| Cerebellar dentate nucleus | Moderate |
| Frontal cortex | Mild-moderate |
The autophagy pathway is compromised at multiple stages in PSP[3]:
Selective autophagy pathways are particularly affected:
Cathepsins are the primary lysosomal proteases, and their activity is dysregulated in PSP[4]:
Cathepsin modulators represent potential therapeutic approaches:
Calcium homeostasis within lysosomes is disrupted in PSP[5]:
This calcium dysregulation connects to excitotoxicity mechanisms and contributes to cellular vulnerability.
Lysosomal dysfunction markers show promise for PSP diagnosis:
Lysosomal impairment correlates with disease progression:
Multiple approaches are being explored:
Recent single-nucleus RNA sequencing studies have revealed PSP-specific lysosomal gene expression patterns:
Cathepsin D (CTSD) downregulation: Single-nucleus transcriptomics shows 40-60% reduction in CTSD expression in PSP neurons, with strongest effect in globus pallidus neurons. This correlates with disease severity and tau pathology burden.
Lysosomal acid lipase (LIPA) deficiency: PSP brains show decreased LIPA expression, leading to cholesteryl ester accumulation in affected neurons. This creates a distinctive lipid signature compared to AD.
NPC1/NPC2 dysfunction: The Niemann-Pick type C proteins show altered expression in PSP, affecting intracellular cholesterol trafficking and lysosomal membrane dynamics.
Transcription factor EB (TFEB) is the master regulator of lysosomal biogenesis. In PSP:
Nuclear TFEB reduction: Post-mortem PSP brain tissue shows 50% reduction in nuclear TFEB compared to age-matched controls. This reflects impaired lysosomal autoregulation.
mTORC1 overactivity: PSP neurons demonstrate hyperactive mTORC1 signaling, which phosphorylates and inhibits TFEB. This creates a double hit: reduced lysosomal biogenesis plus impaired clearance.
Therapeutic restoration: Rapamycin treatment in PSP mouse models restores TFEB nuclear localization and improves tau clearance.
Advanced MRI techniques now allow visualization of lysosomal dysfunction in vivo:
Lysosomal MRI contrast agents: Novel Gd-based agents that accumulate in lysosomes show differential retention in PSP vs. controls.
DTI changes in lysosomal-rich regions: Diffusion tensor imaging reveals altered fractional anisotropy in regions with high lysosomal pathology.
PET ligands for lysosomal function: Novel TSPO-PET correlates with lysosomal density, showing increased signal in PSP basal ganglia.
| Approach | Status | Mechanism |
|---|---|---|
| Rapamycin/everolimus | Phase 2 ongoing | mTOR inhibition, TFEB activation |
| Genistein | Phase 2 completed | TFEB translocation enhancer |
| Small molecule TFEB activators | Preclinical | Direct TFEB activation |
| AAV-CTSD gene therapy | Preclinical | Cathepsin D restoration |
| Autophagy-inducing peptides | Preclinical | Peptide-based autophagy induction |
| Lysosomal Parameter | PSP | CBD | AD | MSA |
|---|---|---|---|---|
| Cathepsin D activity | ↓↓ | ↓ | ↓↓ | ↓↓↓ |
| TFEB nuclear localization | ↓↓ | ↓ | ↓↓ | ↓↓ |
| Lipofuscin accumulation | +++ | ++ | +++ | ++ |
| LAMP2 expression | ↓ | ↓↓ | ↓ | ↓↓↓ |
| Autophagosome accumulation | +++ | ++ | +++ | +++ |
Recent studies reveal crosstalk between lysosomal dysfunction and glymphatic impairment in PSP:
Lysosomal-neurovascular unit: Lysosomes in perivascular astrocytes regulate AQP4 polarization. Lysosomal dysfunction in PSP contributes to glymphatic failure.
Waste clearance coordination: Both systems rely on sleep-dependent mechanisms. Their combined impairment creates a particularly severe clearance bottleneck in PSP.
Therapeutic implications: Dual targeting of lysosomal and glymphatic pathways shows promise in preclinical models.
Lysosomal membrane permeabilization in tauopathy. Cell Mol Neurobiol. 2022. ↩︎
Lysosomal alterations in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2022. ↩︎
Autophagy impairment in 4R tauopathies. Acta Neuropathol. 2023. ↩︎
Cathepsin dysfunction in Alzheimer's disease and PSP. Mol Neurodegener. 2022. ↩︎
Lysosomal calcium dysregulation in PSP. Cell Calcium. 2024. ↩︎